



(51) International Patent Classification:
C07K 16/08 (2006.01) A61P 31/20 (2006.01)

(21) International Application Number:
PCT/US2024/042286

(22) International Filing Date:
14 August 2024 (14.08.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/519,827 15 August 2023 (15.08.2023) US

(71) Applicant: GIGAGEN, INC. [US/US]; 75 Shoreway Road, Suite A, San Carlos, CA 94070 (US).

(72) Inventors: ADLER, Adam, Shultz, GigaGen, Inc., 75 Shoreway Road, Suite A, San Carlos, CA 94070 (US). KEATING, Sheila; GigaGen, Inc., 75 Shoreway Road, Suite A, San Carlos, CA 94070 (US). MIZRAHI, Rena, Aviva; GigaGen, Inc., 75 Shoreway Road, Suite A, San Carlos, CA 94070 (US). GRAS, Ashley, Kristine; GigaGen, Inc., 75 Shoreway Road, Suite A, San Carlos, CA 94070


(US). ASENSIO, Michael; GigaGen, Inc., 75 Shoreway Road, Suite A, San Carlos, CA 94070 (US).

(74) Agent: YOON, Hayan et al.; Fenwick and West LLP, Silicon Valley Center, 801 California Street, Mountain View, CA 94041 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,

(54) Title: RECOMBINANT POLYCLONAL PROTEINS TARGETING HEPATITIS B VIRUS (HBV) AND METHODS OF USE THEREOF



(57) Abstract: Provided herein are pharmaceutical compositions comprising recombinant polyclonal antibodies for treatment of hepatitis B. Specifically, recombinant polyclonal antibodies specific to HBV antigens are provided. Also provided are the methods of making a pharmaceutical composition comprising the recombinant polyclonal antibodies.

[Continued on next page]

DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*